香港张文龙医生;肝癌..肝细胞癌(HCC)是侵袭较强的肝肿瘤,免疫靶向联合疗法是治疗这种难治性肿瘤的新方向。香港临床肿瘤科张文龙医生指出,FDA已批准Atezolizumab与Bevacizumab联用,用于治疗既往未接受过
使用atezolizumab / bevacizumab可使HCC患者的死亡风险降低42%(HR,0.58; 95%CI,0.42-0.79; P = 0.0006),PFS率为41%(HR,0.59; 95%CI, 0.47-0.76;P <0.0001)。联合用药组未达到中位OS,仅索拉非尼组为13.2个月。接受atezolizumab联合贝伐单抗治疗的患者的中位PFS为6.8个月,而索拉非尼组为4.3个月。 在联合治...
德国协会肝病研究学会的Peter R.加勒,医学博士,医学部的大学医学中心的美因茨导演,并当选总统,讨论了从第三阶段IMbrave 150临床试验,评估出来的结果Atezolizumab(Tecentriq)加上bevacizumab(Avastin)与标准治疗方法索拉非尼(Nexavar)的组合作为不可切除的肝细胞癌(HCC)患者的一线治疗。 加勒说,每个周期都要对患者进行分析,...
Hepatocellular carcinoma(HCC)is the most common primary liver cancer.For advanced HCC,sorafenib was considered the standard of care for more than ten years.Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune ...
Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCCStacey Stein, MD, associate professor of internal medicine at the Yale School of Medicine and assistant medical director of the clinical trials office at Yale Cancer Center, discusses the patient population and outcomes of the IMbr...
肝癌患者有望迎来新疗法:新药三联疗法治疗肝癌显现佳绩,58.6%的患者疾病得到控制!美国Coherus BioSciences公司公布了一项2期临床试验的积极数据结果:前沿药Casdozokitug(casdozo)联合阿替利珠单抗(Atezolizumab)及贝伐单抗(Bevacizumab),针对不可切除的局部晚期或转移性肝细胞癌(HCC)患者的初次治疗,产生了令人鼓舞的抗肿瘤...
Singal and Saeed discuss the IMbrave150 study published in 2020, which led to FDA approval of the combination of atezolizumab plus bevacizumab as a first-line treatment for unresectable hepatocellular carcinoma (HCC). This regimen showed superior progression-free and overall survival compared to sorafen...
January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.
Atezolizumab and bevacizumab in advanced HCC: ready for prime time?doi:10.1053/j.gastro.2020.12.013Andrea Casadei-GardiniStefano CascinuMassimo ColomboGastroenterology
A Phase2 study to investigate the efficacy and safety of Atezolizumab and bevacizumab with live bacterial product for unresectable HCC 开始日期2023-08-25 申办/合作机构- NCT05180422 /Withdrawn临床1/2期 A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable...